SIRT4 and neoplasm: Tumor studies have shown that SIRT4 has both oncogenic and tumor‐suppressive activities in cancer depending on the experimental conditions.(71) In the context of 1,25(OH)2D signaling and concomitant ROS reduction, SIRT1/4 downregulation may help create an epigenomic landscape and balance to facilitate 1,25(OH)2D‐specific anticancer transcriptional responses and genomic stability.